Mark Anthony McCamish - 29 Jul 2025 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role
Director
Signature
/s/ Jerad G. Seurer, as Attorney-in-Fact
Issuer symbol
AVDL
Transactions as of
29 Jul 2025
Net transactions value
$0
Form type
4
Filing time
31 Jul 2025, 16:10:52 UTC
Previous filing
01 Aug 2024
Next filing
06 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
McCamish Mark Anthony Director C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND /s/ Jerad G. Seurer, as Attorney-in-Fact 31 Jul 2025 0001390798

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVDL Ordinary Shares Award $0 +11,000 +100% $0.000000 22,000 29 Jul 2025 Direct F1
holding AVDL Ordinary Shares 67,025 29 Jul 2025 By Matthew 5 LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVDL Stock Option (Right to Buy) Award $0 +11,000 $0.000000 11,000 29 Jul 2025 Ordinary Shares 11,000 $10.83 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted share award. The shares shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.
F2 Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager.
F3 The options shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.